{"id":688416,"date":"2022-09-23T08:33:49","date_gmt":"2022-09-23T12:33:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\/"},"modified":"2022-09-23T08:33:49","modified_gmt":"2022-09-23T12:33:49","slug":"sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\/","title":{"rendered":"SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference\u00a0on SAB-176 Phase 2a Influenza Trial and SAB-185\u2019s Effectiveness\u00a0Against Multiple COVID-19 Variants"},"content":{"rendered":"
\n

SIOUX FALLS, S.D., Sept. 23, 2022 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq: SABS), (“SAB\u201d), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, announced today that the Company will present new data on its fully-human polyclonal antibody platform\u2019s ability to maintain its efficacy against multiple variants of several highly mutating viruses at the Options for Control of Influenza (OPTIONS XI) conference, which is hosted by the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) in Belfast, Northern Ireland, from Sept. 26-29, 2022.<\/p>\n

SAB will conduct an oral presentation, titled \u201cEfficacy and Safety of SAB-176, a Novel Anti-Type A and B Influenza Immunotherapeutic: A Phase 2a, Randomized, Double-Blind Trial in H1N1 Challenged Adults,\u201d<\/strong> on Thursday, Sept. 29, at 11: 24 AM BST.<\/p>\n

Additionally, SAB will present a poster, titled \u201cTranschromosomic Bovine-Derived Human Anti-SARS-CoV-2 Polyclonal Antibodies Protect hACE2 Transgenic Syrian Hamsters Against Multiple SARS CoV-2 Variants,\u201d <\/strong>on Tuesday, Sept. 27, from 5:30-7 PM BST.<\/p>\n

\u201cWe look forward to highlighting the power of polyclonal antibodies to neutralize highly mutating viruses and the differentiation of SAB\u2019s novel therapeutic products at the upcoming ISIRV conference,\u201d said Eddie Sullivan, co-founder, President, and Chief Executive Officer of SAB.<\/p>\n

To view the OPTIONS XI program online, please visit:\u00a0https:\/\/www.optionsxi2022.org.uk\/programme<\/a>.<\/p>\n

\n About SAB Biotherapeutics, Inc.<\/strong>\n <\/p>\n

SAB Biotherapeutics, Inc. (SAB) We are a clinical-stage biopharmaceutical company focused on the development of powerful and proprietary immunotherapeutic polyclonal human antibodies to treat and prevent infectious diseases and immune and autoimmune disorders. Our development programs include infectious diseases resulting from outbreaks and pandemics, as well as immunological, gastroenterological, and respiratory diseases that have significant mortality and health impacts on immune compromised patients. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine\u2122. Our versatile DiversitAb\u2122 platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, fully-human polyclonal immunotherapies without the need for human donors. SAB currently has multiple drug development programs underway and collaborations with the US government and global pharmaceutical companies. For more information on SAB, visit:\u00a0https:\/\/www.SAb.bio\/<\/u><\/a>\u00a0and follow SAB on\u00a0Twitter<\/u><\/a>\u00a0and\u00a0LinkedIn<\/u><\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

Certain statements made herein that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201cseem,\u201d \u201cseek,\u201d \u201cfuture,\u201d \u201coutlook\u201d and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including the development and efficacy of our influenza program, C. diff. program, Type 1 Diabetes program, and other discovery programs, the likelihood that a patent will issue from any patent application, the results, including timing, of the development of SAB-195 (including any IND filing or proposed clinical trials), financial projections and future financial and operating results (including estimated cost savings and cash runway), the outcome of and potential future government and other third-party collaborations or funded programs (including negotiations with the DoD). These statements are based on the current expectations of SAB and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry\u2019s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned \u201cRisk Factors\u201d in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at\u00a0https:\/\/www.sec.gov\/<\/u><\/a>\u00a0Except as otherwise required by law, SAB disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.<\/p>\n

\n CONTACTS:<\/strong>\n <\/p>\n

\n Investor Relations:<\/strong>
\n
\n
\n SABIR@westwicke.com<\/a>
\n <\/u>\n <\/p>\n

\n Media Relations:<\/strong>
\n
\n
\n SABPR@westwicke.com<\/a>
\n <\/u>\n <\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SIOUX FALLS, S.D., Sept. 23, 2022 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq: SABS), (“SAB\u201d), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, announced today that the Company will present new data on its fully-human polyclonal antibody platform\u2019s ability to maintain its efficacy against multiple variants of several highly mutating viruses at the Options for Control of Influenza (OPTIONS XI) conference, which is hosted by the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) in Belfast, Northern Ireland, from Sept. 26-29, 2022. SAB will conduct an oral presentation, titled \u201cEfficacy and Safety of SAB-176, a Novel Anti-Type A and B Influenza Immunotherapeutic: A Phase … <\/p>\n

Continue reading “SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference\u00a0on SAB-176 Phase 2a Influenza Trial and SAB-185\u2019s Effectiveness\u00a0Against Multiple COVID-19 Variants”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-688416","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference\u00a0on SAB-176 Phase 2a Influenza Trial and SAB-185\u2019s Effectiveness\u00a0Against Multiple COVID-19 Variants - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference\u00a0on SAB-176 Phase 2a Influenza Trial and SAB-185\u2019s Effectiveness\u00a0Against Multiple COVID-19 Variants - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SIOUX FALLS, S.D., Sept. 23, 2022 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq: SABS), (“SAB\u201d), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, announced today that the Company will present new data on its fully-human polyclonal antibody platform\u2019s ability to maintain its efficacy against multiple variants of several highly mutating viruses at the Options for Control of Influenza (OPTIONS XI) conference, which is hosted by the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) in Belfast, Northern Ireland, from Sept. 26-29, 2022. SAB will conduct an oral presentation, titled \u201cEfficacy and Safety of SAB-176, a Novel Anti-Type A and B Influenza Immunotherapeutic: A Phase … Continue reading "SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference\u00a0on SAB-176 Phase 2a Influenza Trial and SAB-185\u2019s Effectiveness\u00a0Against Multiple COVID-19 Variants"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-23T12:33:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjA4NiM1MTY4MjcyIzIyMjE3NDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference\u00a0on SAB-176 Phase 2a Influenza Trial and SAB-185\u2019s Effectiveness\u00a0Against Multiple COVID-19 Variants\",\"datePublished\":\"2022-09-23T12:33:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\\\/\"},\"wordCount\":775,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjA4NiM1MTY4MjcyIzIyMjE3NDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\\\/\",\"name\":\"SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference\u00a0on SAB-176 Phase 2a Influenza Trial and SAB-185\u2019s Effectiveness\u00a0Against Multiple COVID-19 Variants - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjA4NiM1MTY4MjcyIzIyMjE3NDE=\",\"datePublished\":\"2022-09-23T12:33:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjA4NiM1MTY4MjcyIzIyMjE3NDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjA4NiM1MTY4MjcyIzIyMjE3NDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference\u00a0on SAB-176 Phase 2a Influenza Trial and SAB-185\u2019s Effectiveness\u00a0Against Multiple COVID-19 Variants\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference\u00a0on SAB-176 Phase 2a Influenza Trial and SAB-185\u2019s Effectiveness\u00a0Against Multiple COVID-19 Variants - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\/","og_locale":"en_US","og_type":"article","og_title":"SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference\u00a0on SAB-176 Phase 2a Influenza Trial and SAB-185\u2019s Effectiveness\u00a0Against Multiple COVID-19 Variants - Market Newsdesk","og_description":"SIOUX FALLS, S.D., Sept. 23, 2022 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq: SABS), (“SAB\u201d), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, announced today that the Company will present new data on its fully-human polyclonal antibody platform\u2019s ability to maintain its efficacy against multiple variants of several highly mutating viruses at the Options for Control of Influenza (OPTIONS XI) conference, which is hosted by the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) in Belfast, Northern Ireland, from Sept. 26-29, 2022. SAB will conduct an oral presentation, titled \u201cEfficacy and Safety of SAB-176, a Novel Anti-Type A and B Influenza Immunotherapeutic: A Phase … Continue reading \"SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference\u00a0on SAB-176 Phase 2a Influenza Trial and SAB-185\u2019s Effectiveness\u00a0Against Multiple COVID-19 Variants\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-23T12:33:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjA4NiM1MTY4MjcyIzIyMjE3NDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference\u00a0on SAB-176 Phase 2a Influenza Trial and SAB-185\u2019s Effectiveness\u00a0Against Multiple COVID-19 Variants","datePublished":"2022-09-23T12:33:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\/"},"wordCount":775,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjA4NiM1MTY4MjcyIzIyMjE3NDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\/","name":"SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference\u00a0on SAB-176 Phase 2a Influenza Trial and SAB-185\u2019s Effectiveness\u00a0Against Multiple COVID-19 Variants - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjA4NiM1MTY4MjcyIzIyMjE3NDE=","datePublished":"2022-09-23T12:33:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjA4NiM1MTY4MjcyIzIyMjE3NDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjA4NiM1MTY4MjcyIzIyMjE3NDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-biotherapeutics-to-present-new-data-at-isirv-options-xi-conference-on-sab-176-phase-2a-influenza-trial-and-sab-185s-effectiveness-against-multiple-covid-19-variants\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference\u00a0on SAB-176 Phase 2a Influenza Trial and SAB-185\u2019s Effectiveness\u00a0Against Multiple COVID-19 Variants"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688416","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=688416"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688416\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=688416"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=688416"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=688416"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}